NUVATION BIO
nuvationbio.com
Actively hiring
Health Care
Oncology Therapeutics
Drug Discovery
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Nuvation Bio Announces Fda Approval of Supplemental New Drug Application for Ibtrozi (Taletrectinib) with Updated Duration of Response in Tki-Naive Advanced Ros1-Positive Non ...
Read more
Report
Nuvation Bio (NUVB) Reports IBTROZI Efficacy Across ROS1 Lung Cancer Subgroups
Nuvation Bio (NYSE:NUVB) presented new subgroup analyses of IBTROZI (taletrectinib) at the 2026 World Conference on Lung Cancer. The data indicated durable and consistent efficacy in advanced ROS1+ non small cell lung cancer regardless of prior chemothera
Read more
Report
Taletrectinib Across Key Subgroups in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From TRUST-I and TRUST-II
The post Taletrectinib Across Key Subgroups in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From TRUST-I and TRUST-II appeared first on NUVATION BIO, INC..
Read more
Report
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update - Company Announcement - FT.com
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report
Comparative Efficacy of Taletrectinib Versus First-Generation TKIs in TKI-Naïve ROS1+ Non-Small Cell Lung Cancer: A Matching-Adjusted Indirect Comparison
The post Comparative Efficacy of Taletrectinib Versus First-Generation TKIs in TKI-Naïve ROS1+ Non-Small Cell Lung Cancer: A Matching-Adjusted Indirect Comparison appeared first on NUVATION BIO, INC..
Read more
Report
Pro access
Upgrade to see all 20 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
People
David Hung M.D.
Executive Officer, Director
Kim Blickenstaff
Director
Michelle Doig
Director
Kathryn Falberg
Director
Claudio Nessi
Director
W. Vernon
Director
Daniel Welch
Director
Robert Bazemore
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
2
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Shanghai
China
Regional office
China
118 Ruijin Second Road, Huangpu District,, Shanghai 200021, China
Financials
Total raised
$275.3M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2019 | $275.3M | Details |